HS
AKBA icon

HighVista Strategies’s Akebia Therapeutics AKBA Stock Holding History

HighVista Strategies’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-11,800
Closed -$160K – 114
2020
Q2 		$160K Hold
11,800
– – 0.13% 72
2020
Q1 		$89K Sell
11,800
-1,900
-14% -$14.8K 0.08% 27
2019
Q4 		$87K Sell
13,700
-1,100
-7% -$5.23K 0.07% 86
2019
Q3 		$58K Buy
+14,800
New +$63.4K 0.04% 110

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighVista Strategies's AKBA Position: Q3 2020 in Review

HighVista Strategies sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 11,800 shares — an estimated $160K sold.

HighVista Strategies first reported a position in AKBA in Q3 2019 and held it in 4 quarters. The position peaked at $160K in Q2 2020. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

  • HighVista Strategies reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • HighVista Strategies sold 11,800 Akebia Therapeutics shares in Q3 2020, an estimated $160K.
  • HighVista Strategies first reported a position in Akebia Therapeutics in Q3 2019 and held it in 4 quarters.
  • HighVista Strategies's Akebia Therapeutics position peaked at $160K in Q2 2020.
  • 164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on HighVista Strategies's 13F filing for Q3 2020, filed 16 Nov 2020.